已存在的新生血管性年龄相关性黄斑变性患者接受空白性脑萎缩治疗的真实世界结果

Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2024-12-27 eCollection Date: 2024-01-01 DOI:10.2147/OPTH.S497678
Ryan B Rush, Westin Klein, Sloan W Rush, Robert M Reinauer
{"title":"已存在的新生血管性年龄相关性黄斑变性患者接受空白性脑萎缩治疗的真实世界结果","authors":"Ryan B Rush, Westin Klein, Sloan W Rush, Robert M Reinauer","doi":"10.2147/OPTH.S497678","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate real-world outcomes in subjects with pre-existing neovascular age-related macular degeneration (AMD) undergoing intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA).</p><p><strong>Methods: </strong>This study was undertaken as a retrospective, case-controlled assessment of patients undergoing IVA treatment for GA from 2 community-based retina practices. Patients were separated into 1) a Study Group consisting of subjects with pre-existing neovascular AMD prior to initiation of IVA for GA, and 2) a Control Group consisting of AMD subjects without neovascularization prior to initiation of IVA for GA. Study and Control Group subjects had a baseline visual acuity of ≥ 20/200, a total GA lesion area of ≥ 1 mm<sup>2</sup> and ≤ 17.5 mm<sup>2</sup>, and follow-up of 12-months following IVA commencement.</p><p><strong>Results: </strong>A total of 64 patients were analyzed. No significant differences in baseline characteristics were found between cohorts. The Study Group had a greater decrease in visual acuity [-0.2 (-0.24 to -0.16) logMAR versus -0.04 (-0.06 to 0.02) logMAR; p<0.0001], a greater increase in GA lesion growth [1.36 (1.09-1.63) mm<sup>2</sup> versus 0.52 (0.34-0.70) mm<sup>2</sup>; p<0.0001], and a higher incidence of exudation (p=0.0002) compared to the Control Group during the study period.</p><p><strong>Conclusion: </strong>This study suggests that patients undergoing IVA therapy for GA with pre-existing neovascular AMD have worse visual and anatomic outcomes at 12-months compared to a matched control group without pre-existing neovascularization; such patients therefore should be carefully counseled prior to initiation of IVA for the management of GA.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"4011-4018"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11687279/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy.\",\"authors\":\"Ryan B Rush, Westin Klein, Sloan W Rush, Robert M Reinauer\",\"doi\":\"10.2147/OPTH.S497678\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate real-world outcomes in subjects with pre-existing neovascular age-related macular degeneration (AMD) undergoing intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA).</p><p><strong>Methods: </strong>This study was undertaken as a retrospective, case-controlled assessment of patients undergoing IVA treatment for GA from 2 community-based retina practices. Patients were separated into 1) a Study Group consisting of subjects with pre-existing neovascular AMD prior to initiation of IVA for GA, and 2) a Control Group consisting of AMD subjects without neovascularization prior to initiation of IVA for GA. Study and Control Group subjects had a baseline visual acuity of ≥ 20/200, a total GA lesion area of ≥ 1 mm<sup>2</sup> and ≤ 17.5 mm<sup>2</sup>, and follow-up of 12-months following IVA commencement.</p><p><strong>Results: </strong>A total of 64 patients were analyzed. No significant differences in baseline characteristics were found between cohorts. The Study Group had a greater decrease in visual acuity [-0.2 (-0.24 to -0.16) logMAR versus -0.04 (-0.06 to 0.02) logMAR; p<0.0001], a greater increase in GA lesion growth [1.36 (1.09-1.63) mm<sup>2</sup> versus 0.52 (0.34-0.70) mm<sup>2</sup>; p<0.0001], and a higher incidence of exudation (p=0.0002) compared to the Control Group during the study period.</p><p><strong>Conclusion: </strong>This study suggests that patients undergoing IVA therapy for GA with pre-existing neovascular AMD have worse visual and anatomic outcomes at 12-months compared to a matched control group without pre-existing neovascularization; such patients therefore should be carefully counseled prior to initiation of IVA for the management of GA.</p>\",\"PeriodicalId\":93945,\"journal\":{\"name\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"volume\":\"18 \",\"pages\":\"4011-4018\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11687279/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/OPTH.S497678\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S497678","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:评估已存在的新生血管性年龄相关性黄斑变性(AMD)患者在接受玻璃体内avacincaptad pegol (IVA)治疗地理萎缩(GA)时的实际结果。方法:本研究对来自2个社区视网膜诊所接受静脉注射治疗的GA患者进行回顾性、病例对照评估。患者被分为两组:1)研究组,包括在GA的IVA治疗开始前已经有新生血管性AMD的患者;2)对照组,包括在GA的IVA治疗开始前没有新生血管性AMD的患者。研究和对照组受试者基线视力≥20/200,GA总病变面积≥1mm2≤17.5 mm2, IVA开始后随访12个月。结果:共分析64例患者。在队列之间没有发现基线特征的显著差异。研究组的视力下降幅度更大[-0.2(-0.24至-0.16)logMAR相比-0.04(-0.06至0.02)logMAR;P2 vs 0.52 (0.34-0.70) mm2;结论:本研究表明,与没有新生血管形成的对照组相比,接受IVA治疗的GA合并新生血管性AMD患者在12个月时的视觉和解剖结果更差;因此,在开始IVA治疗GA之前,应仔细咨询此类患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy.

Purpose: To evaluate real-world outcomes in subjects with pre-existing neovascular age-related macular degeneration (AMD) undergoing intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA).

Methods: This study was undertaken as a retrospective, case-controlled assessment of patients undergoing IVA treatment for GA from 2 community-based retina practices. Patients were separated into 1) a Study Group consisting of subjects with pre-existing neovascular AMD prior to initiation of IVA for GA, and 2) a Control Group consisting of AMD subjects without neovascularization prior to initiation of IVA for GA. Study and Control Group subjects had a baseline visual acuity of ≥ 20/200, a total GA lesion area of ≥ 1 mm2 and ≤ 17.5 mm2, and follow-up of 12-months following IVA commencement.

Results: A total of 64 patients were analyzed. No significant differences in baseline characteristics were found between cohorts. The Study Group had a greater decrease in visual acuity [-0.2 (-0.24 to -0.16) logMAR versus -0.04 (-0.06 to 0.02) logMAR; p<0.0001], a greater increase in GA lesion growth [1.36 (1.09-1.63) mm2 versus 0.52 (0.34-0.70) mm2; p<0.0001], and a higher incidence of exudation (p=0.0002) compared to the Control Group during the study period.

Conclusion: This study suggests that patients undergoing IVA therapy for GA with pre-existing neovascular AMD have worse visual and anatomic outcomes at 12-months compared to a matched control group without pre-existing neovascularization; such patients therefore should be carefully counseled prior to initiation of IVA for the management of GA.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信